Comparison of serum profile of inflammatory cytokines in localized prostate cancer patients

Not Applicable

Recruiting

• Conditions: Prostate Cancer.

• Registration Number: IRCT20211004052674N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

Age =18 year
Eastern Cooperative Oncology Group (ECOG) performance zero or one
Localized prostate adenocarcinoma confirmed by pathology with moderate (Unfavorable) and high risk according to National Comprehensive Cancer Network criteria(NCCN) (first edition 2021)

Exclusion Criteria

Severe physical illness or mental disorder that, according to the researcher, prevents treatment according to the protocol
Patients who cannot be followed up regularly
Contraindications for external radiotherapy or brachytherapy
Previous history of external radiotherapy or prostate brachytherapy
History of any prostate surgery
Any history of malignancy (except for non-melanoma skin cancers)
History of Chemotherapy, Targeted Therapy and the use of immunosuppressive drugs
History of chronic infectious diseases (HIV, viral hepatitis, etc.)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum profile of inflammatory cytokines. Timepoint: Serum levels of inflammatory cytokines are measured two weeks before the start of radiotherapy, and one and three months after the end of radiotherapy. Method of measurement: Blood test.